ARTICLE | Finance
B round for Be Bio’s B cells: Arch leads $130M funding for cell engineering start-up
Engineered B cell platform company Be Bio moves autologous therapies toward clinic, attracts Arch with allogeneic strategy
April 14, 2022 10:12 PM UTC
Although Be Bio isn’t yet disclosing any details of its nascent pipeline programs, the engineered B cell therapy developer intends to use its new $130 million series B round to beef up ...